Tag Archives: colon cancer prevention

Statement from Carlea Bauman, President of Fight Colorectal Cancer, Regarding the President’s 2014 Budget

I am deeply disappointed that President Obama’s fiscal year (FY) 2014 budget would strip nearly $4 million from the Centers for Disease Control and Prevention’s (CDC) Colorectal Cancer Control Program. The CDC estimates that the loss of funding will mean at least five fewer programs (out of the current 29) working to prevent colorectal cancer. The president’s budget assumes that less federal funding is needed for direct screenings, such as colorectal, breast, and cervical screenings, because most health plans are required to cover these screenings without co-pays or deductibles, and because, starting in 2014, the Affordable Care Act ensures that no one can be denied health insurance because of a

Colon Cancer Prevention Trial Seeking New Patients

Can drugs used to help lower cholesterol also keep colon cancer from returning?  Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) are seeking patients for a one-year clinical trial to determine if cholesterol-lowering drugs (statins) might help prevent the growth of precancerous (adenomatous) polyps and/or recurrent colorectal cancer. The NSABP trial is sponsored by the National Cancer Institute and has recently expanded to include patients with stage 0, I, II or III colon cancer at diagnosis. Patients can enter the study up to one year after their initial diagnosis. In 2011, Fight Colorectal Cancer’s late Director of Research Communications Kate Murphy wrote about the trial and its efforts

CDC Mulls Self-Evaluation; Fight Colorectal Cancer Sends Letter of Support

The Centers for Disease Control and Prevention (CDC) has proposed an evaluation of its federally funded Colorectal Cancer Control Program to determine whether the program does what is it supposed to do: Increase state-level colorectal cancer screening rates and other related outcomes.

Diet and Exercise Habits Strongly Related to Higher Rates of CRC in People with Lower Education and/or Income

Fewer people in the U.S. are getting colorectal cancer (CRC), but that progress is seen much more often in well-off and highly educated Americans. In fact, the gap is widening in rate of colorectal deaths in people with less education and/or who live in deeply disadvantaged communities. Researchers now have shown that differences in weight, diet and physical activity play a huge role in the higher rates and deaths from CRC among people of lower socioeconomic status. In a paper published in the Sept. 4 2012 Journal of the National Cancer Institute, a careful statistical analysis of  a 10-year observational study of a half-million people indicated that helping people of lower

Diabetes Linked to Death from Colorectal Cancer

Being diagnosed with Type 2 diabetes makes it more likely that men and women with colorectal cancer will die from colon or rectal cancer, from cardiovascular disease, or from any cause. Diabetes increased risk of dying from colorectal cancer about 30 percent and more than doubled chances of dying from heart disease or stroke.  Overall deaths among early stage colon and rectal cancer patients was increased about 50 percent when they had diabetes before their colorectal cancer diagnosis. For patients initially diagnosed with stage I, II, or III cancer, the chance of not dying from colorectal cancer within 5 years was 82 percent with Type 2 diabetes and 87 percent

New Opportunity for Patients Finishing Colon Cancer Treatment

Are you finished with surgery or chemotherapy for early stage colon cancer? Would you like a chance to see if a new experimental treatment can reduce your risk of A new polyp in your colon? Colon cancer spreading beyond your colon? A new colon cancer? Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) would like to talk to you about a clinical trial exploring whether a statin drug can reduce the risk of new polyps, colon cancer recurrence, or a new primary colon cancer. In the P-5 clinical trial stage I and II colon cancer patients will be randomly assigned to take either rosuvastatin (Crestor®) or an